Skip to content
Clinical Trials – home

Uniwersyteckie Centrum Kliniczne

Verified siteinfo

Poland Ul. Mariana Smoluchowskiego 17, 80-214 Gdansk, Poland

  • 215 trials recruiting
  • Non-small cell lung cancer · Plasma cell myeloma · Neoplasm
  • Adults and children

About Specializations

Uniwersyteckie Centrum Kliniczne in Gdansk, Poland specialises in clinical trials of conditions such as Non-small cell lung cancer, Plasma cell myeloma, Neoplasm, Acute myeloid leukaemia, and other specialisations. This site conducts important research.

Main research areas of the site

Immune System Diseases

At Uniwersyteckie Centrum Kliniczne in Gdansk, research in immune system diseases focuses on conditions such as myasthenia gravis and the prevention of Herpes Zoster in immunocompromised children and adolescents. These studies are designed to better understand treatment response, immune protection, and overall safety in younger patients.

  • Evaluating new treatment options for generalized myasthenia gravis in children and adolescents
  • Studying pediatric Herpes Zoster prevention in immunocompromised patients
  • Assessing immune response and safety in pediatric populations

This area of research supports improved care for children with complex immune-related conditions, with a strong emphasis on therapy effectiveness and protection against infection.

Nervous System Diseases

Clinical trials in nervous system diseases at this site examine relapsing-remitting multiple sclerosis and spinal muscular atrophy, with the goal of improving treatment outcomes for pediatric patients. The work includes efforts to evaluate how well therapies are tolerated and how they affect disease control and functional development.

  • Investigating treatment effects in relapsing-remitting multiple sclerosis
  • Exploring therapy response in spinal muscular atrophy
  • Supporting better disease management in children and adolescents

The research reflects a broad commitment to advancing care in pediatric neurology, especially for conditions that can significantly affect movement, strength, and long-term neurological health.

Musculoskeletal Diseases

Studies in musculoskeletal diseases at Uniwersyteckie Centrum Kliniczne are closely linked to disorders that affect muscle function and physical ability, particularly spinal muscular atrophy and myasthenia gravis. These trials aim to determine whether emerging therapies can improve strength, mobility, and everyday functioning in young patients.

  • Examining therapies for muscle weakness and impaired movement
  • Focusing on functional improvement in spinal muscular atrophy
  • Assessing treatment benefit in myasthenia gravis

This research area helps clarify how new approaches may support better physical outcomes and quality of life for children living with neuromuscular conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Site location
Ul. Mariana Smoluchowskiego 1780-214 GdanskPoland
Recruiting now
215 trials
Conditions studied
289
Partner status
Verified site

More sites in GdanskPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

567 clinical trials

Study of once weekly subcutaneous zenagamtide versus placebo in adults with type 2 diabetes and chronic kidney disease on basal insulin

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Face and Neck Atopic Dermatitis

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Asthma

Recruiting

Safety and Tolerability of Benralizumab in Patients with HES, EGPA, or Asthma Who Completed a Prior Study

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:AstraZeneca AB

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

A study to evaluate the effects of zenagamtide in people with overweight or obesity and obstructive sleep apnoea not treated with positive airway pressure

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Study of zenagamtide for weight loss and sleep improvement in patients with obesity and obstructive sleep apnea using positive airway pressure therapy

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Breast cancer

Recruiting

Study of BNT327 and a drug combination for patients with untreated metastatic or locally recurrent triple-negative breast cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:BioNTech SE

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Myelofibrosis+3

Recruiting

Study of RVU120 treatment in patients with myelodysplastic syndrome, solid tumors, or acute myeloid leukemia who benefited from previous RVU120 therapy

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Ryvu Therapeutics S.A.

Vitiligo+2

Recruiting

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Anastrozole
  • Sponsor:Unicancer
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.